COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD ZincZn
HC Q study #12
Source   PDF   Share   Tweet
See all 155 studies
4/14
Negative
Late treatment study
Tang et al., BMJ 2020, 369, doi:10.1136/bmj.m1849 (Peer Reviewed)
Hydroxych loroquine in patients with COVID-19: an open-label, randomized, controlled trial
150 patients very late stage RCT showing no significant difference. Treatment very late, average 16.6 days after symptom onset.
Data favorable to HC Q was deleted in the second version, see analysis [1].
"[HC Q] accelerate[s] the alleviation of clinical symptoms"
"More rapid alleviation of clinical symptoms with SOC plus HC Q than with SOC alone was observed during the second week since randomization".
"The efficacy of HC Q on the alleviation of symptoms, HR 8.83 [1.09-71.3], was more evident when the confounding effects of other anti-viral agents were removed"
no virological cure, ↓21.5%, p=0.51, risk of no virological cure at day 21
Source   PDF   Share   Tweet
See all 155 studies
Please send us corrections, updates, or comments.
Submit